RE: Alzheimer asset could be valuable31 Jul 2023 07:25
The Company believes it has a leading position in aptamer technology, a technology that the Company believes can make significant inroads into the annual c.$171 billion affinity ligand market. The business model aims to deliver both recurring fee-for-service revenue, and higher risk, higher value licensing revenue that could contribute significant incremental revenues through upfront, milestones and royalty payments.
The Company believes the fee-for-service business provides a robust foundation for revenue growth and is expected to scale over the coming years, following the investments made post IPO. This fee-for-service business has historically partnered with 15 of the top 20 pharmaceutical companies globally and many smaller life sciences companies. This diversified customer base allows the Company to horizon scan and pursue the most exciting opportunities for aptamer technology